The U.S. FDA has declined to approve MDMA-assisted therapy for patients with post-traumatic stress disorder, citing that it could not be approved based on data submitted to them.| Healing Breakthrough
Lykos Therapeutics details how it is addressing questions raised by FDA advisors during a June 4 advisory meeting and how it will apply these insights to its Risk Evaluation and Mitigation Strategy.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
As Lykos Therapeutics considers a Risk Evaluation and Mitigation Strategy for MDMA-assisted therapy, both supporters and detractors of MDMA-AT make their case for whether the treatment is safe for patients.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
The MAPS nonprofit remains the largest shareholder, but gives up controlling interest in MAPS PBC, as the for-profit company that seeks to commercialize MDMA therapy successfully attracts investors.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
As Lykos Therapeutics awaits an FDA decision this week on its proposed MDMA-assisted therapy for PTSD, the company has announced new initiatives and measures for additional oversight if the therapy is approved.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
U.S. Food and Drug Administration requests additional Phase 3 study Issues raised in CRL echo those discussed in FDA Advisory Committee hearing The Company intends to pursue all available...| Lykos Therapeutics - News Release Archive
Lykos Therapeutics addresses concerns from FDA Advisors about MDMA-assisted therapy and presents a forward looking plan.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
